DOVE

DOVE interprets variants in the DMD gene to standardize variant nomenclature and predict molecular eligibility and potential deleterious consequences of therapies such as antisense oligonucleotides (AONs) for Duchenne muscular dystrophy.

Key Features:

• Variant interpretation: Interprets colloquial and Human Gene Mutation Database (HGMD) variant descriptions and converts them into standardized HGMD variant nomenclature.
• Molecular eligibility prediction: Predicts variant-specific molecular eligibility for therapies, including antisense oligonucleotides (AONs), using holistic in silico methods rather than predefined variant-eligible lists.
• Deleterious consequence analysis: Provides predictions of potential deleterious molecular consequences of proposed therapies to inform risk–benefit assessments.
• Integration with existing tools: Integrates existing open-access bioinformatics tools without depending on prior variant reports or classifications.
• Implementation: Implemented in Python and adapted to the Django Web framework.

Scientific Applications:

• Precision-therapy eligibility assessment: Guides molecular eligibility assessments for precision therapies in Duchenne muscular dystrophy clinical and research contexts.
• Newborn screening and large-scale programs: Supports rapid variant interpretation for large-scale programs such as newborn screening.
• General molecular genetics: Facilitates molecular genetic test result interpretation beyond DMD.

Methodology:

Parses colloquial and HGMD inputs, converts variants to standardized HGMD nomenclature, applies holistic in silico methods to assess therapy eligibility and predicted deleterious consequences, integrates open-access tools, and is implemented in Python with adaptation to the Django Web framework while operating without requiring prior variant reports or classifications.